NCT02962063 2025-09-05
Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
Clinical Trials
9 trialsNCT02735239 2024-03-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT02530437 2023-07-10
Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03995017 2023-02-01
RiME
University of Kansas Medical Center
Phase 1/2 Unknown
NCT03307941 2017-12-19
ARTEMIS-Eso
Jules Bordet Institute
Phase 1/2 Withdrawn
NCT00544362 2016-05-30
Fluorouracil, Cisplatin, Cetuximab, and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery
Federation Francophone de Cancerologie Digestive
Phase 1/2 Completed
NCT00093652 2015-10-06
Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT00445861 2012-06-11
Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery
Swiss Cancer Institute
Phase 1/2 Completed
NCT00002984 2012-05-24
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced or Metastatic Cancer of the Esophagus
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Completed